Literature DB >> 20570063

The immunogenicity of DNA constructs co-expressing GP5 and M proteins of porcine reproductive and respiratory syndrome virus conjugated by GPGP linker in pigs.

Min-Yuan Chia1, Shih-Hsuan Hsiao, Hui-Ting Chan, Yi-Yin Do, Pung-Ling Huang, Hui-Wen Chang, Yi-Chieh Tsai, Chun-Ming Lin, Victor Fei Pang, Chian-Ren Jeng.   

Abstract

The heterodimer of glycoprotein 5 (GP5) and non-glycosylated matrix protein (M) is the leading target for the development of new generation of vaccines against porcine reproductive and respiratory syndrome virus (PRRSV) infection. It has been demonstrated that DNA vaccine co-expressing GP5 and M proteins as a fusion protein aroused better immunogenicity than that expressing GP5 or M alone, but it was no better than the DNA vaccine co-expressing GP5 and M proteins with two different promoters. Altered natural conformation of the co-expressed GP5 and M fusion protein was considered as the major cause. Glycine-proline-glycine-proline (GPGP) linker can minimize the conformational changes in tertiary structure and provide flexibility of the peptide chain. The objective of this study was to evaluate whether the immunogenicity of DNA constructs co-expressing GP5 and M proteins linked by GPGP could be enhanced in pigs. Three recombinant DNA constructs expressing GP5/M fusion protein without GPGP linker (pcDNA-56), GP5/M fusion protein conjugated by GPGP linker (pcDNA-5L6), and M/GP5 fusion protein conjugated by GPGP linker (pcDNA-6L5) were established. Sixteen PRRSV-free pigs were randomly assigned to four groups and inoculated intramuscularly with 3 consecutive doses of 500 μg of empty vector pcDNA3.1, pcDNA-56, pcDNA-5L6 or pcDNA-6L5 each at a 2-week interval followed by challenge with 5 × 10(5) TCID(50) PRRSV at 3 weeks after the final inoculation. All pcDNA-56-, pcDNA-5L6-, and pcDNA-6L5- but not pcDNA-3.1-inoculated pigs developed neutralizing antibodies (NAs) 3 weeks after the final inoculation and a gradual increase in NA titers after PRRSV challenge, indicating that pigs inoculated with these DNA constructs could establish a sufficient immune memory. The pcDNA-5L6- and pcDNA-6L5-inoculated pigs displayed lower level and shorter period of viremia and lower tissue viral load following PRRSV challenge than did the pcDNA-56-inoculated pigs. The strategy of co-expressing GPGP-linked GP5 and M fusion protein may be a promising approach for future PRRSV vaccine development, possibly via the improvement of natural conformation of the target fusion protein.
Copyright © 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20570063     DOI: 10.1016/j.vetmic.2010.05.007

Source DB:  PubMed          Journal:  Vet Microbiol        ISSN: 0378-1135            Impact factor:   3.293


  11 in total

1.  Tandem 3' UTR Patterns and Gene Expression Profiles of Marc-145 Cells During PRRSV Infection.

Authors:  Ying Wei; Jie Li; Yun Zhang; Chunyi Xue; Yongchang Cao
Journal:  Virol Sin       Date:  2018-08-01       Impact factor: 4.327

2.  Effects of the fusion design and immunization route on the immunogenicity of Ag85A-Mtb32 in adenoviral vectored tuberculosis vaccine.

Authors:  Yiling Zhang; Liqiang Feng; Liang Li; Dimin Wang; Chufang Li; Caijun Sun; Pingchao Li; Xuehua Zheng; Yichu Liu; Wei Yang; Xuefeng Niu; Nanshan Zhong; Ling Chen
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

3.  The Cholera Toxin B Subunit (CTB) Fused to the Porcine Arterivirus Matrix M and GP5 Envelope Proteins Fails to Enhance the GP5-Specific Antibody Response in Pigs Immunized with Adenovectors.

Authors:  Elodie Roques; Martin Lessard; Denis Archambault
Journal:  Mol Biotechnol       Date:  2015-08       Impact factor: 2.695

4.  Immune responses in mice vaccinated with virus-like particles composed of the GP5 and M proteins of porcine reproductive and respiratory syndrome virus.

Authors:  Hae-Mi Nam; Kyung-Sil Chae; Young-Jo Song; Nak-Hyung Lee; Joong-Bok Lee; Seung-Yong Park; Chang-Seon Song; Kun-Ho Seo; Sang-Moo Kang; Min-Chul Kim; In-Soo Choi
Journal:  Arch Virol       Date:  2013-02-08       Impact factor: 2.574

5.  Immune responses in pigs induced by recombinant DNA vaccine co-expressing swine IL-18 and membrane protein of porcine reproductive and respiratory syndrome virus.

Authors:  Xiaodong Zhang; Xiaoli Wang; Lianzhi Mu; Zhuang Ding
Journal:  Int J Mol Sci       Date:  2012-05-11       Impact factor: 6.208

6.  Assessment of Antibodies Induced by Multivalent Transmission-Blocking Malaria Vaccines.

Authors:  Vinay Menon; Melissa C Kapulu; Iona Taylor; Kerry Jewell; Yuanyuan Li; Fergal Hill; Carole A Long; Kazutoyo Miura; Sumi Biswas
Journal:  Front Immunol       Date:  2018-01-19       Impact factor: 7.561

7.  Assessment of the efficacy of two novel DNA vaccine formulations against highly pathogenic Porcine Reproductive and Respiratory Syndrome Virus.

Authors:  Luping Du; Fengjiao Pang; Zhengyu Yu; Xiangwei Xu; Baochao Fan; Kehe Huang; Kongwang He; Bin Li
Journal:  Sci Rep       Date:  2017-02-03       Impact factor: 4.379

8.  Evaluation of Different DNA Vaccines against Porcine Reproductive and Respiratory Syndrome (PRRS) in Pigs.

Authors:  Stefano Petrini; Giorgio Ramadori; Riccardo Villa; Paolo Borghetti; Elena de Angelis; Anna Maria Cantoni; Attilio Corradi; Augusto Amici; Maura Ferrari
Journal:  Vaccines (Basel)       Date:  2013-10-18

9.  Positive effects of porcine IL-2 and IL-4 on virus-specific immune responses induced by the porcine reproductive and respiratory syndrome virus (PRRSV) ORF5 DNA vaccine in swine.

Authors:  Deyuan Tang; Jian Liu; Chunyan Li; Hua Zhang; Ping Ma; Xianfeng Luo; Zhiyong Zeng; Nining Hong; Xia Liu; Bin Wang; Feng Wang; Zhenlei Gan; Fei Hao
Journal:  J Vet Sci       Date:  2013-10-18       Impact factor: 1.672

10.  Selected SNARE proteins are essential for the polarized membrane insertion of igf-1 receptor and the regulation of initial axonal outgrowth in neurons.

Authors:  Diego Grassi; Florentyna Bustos Plonka; Mariana Oksdath; Alvaro Nieto Guil; Lucas J Sosa; Santiago Quiroga
Journal:  Cell Discov       Date:  2015-09-01       Impact factor: 10.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.